dr. J. (Jaap-Jan) Boelens Associate Professor - medical
- SCT patient care
Jaap-Jan Boelens is a pediatrician – oncologist/Immunologist. He received his PhD at the University of Amsterdam/Academic Medical Center in 1999. He was trained as a paediatrician in the Leiden UMC and the Juliana Children’s Hospital in Den Haag followed by completion of clinical fellowship in immunology (2006, UMC Utrecht) and oncology (2011, ErasmusMC, Rotterdam). His clinical sub-specialization is Hemapoietic Cell Transplantation (HCT) and he is working as a consultant in HCT at the UMC Utrecht since 2006.
He has a special interest in rare-diseases (as indication for HCT) in particular “lysosomal storage diseases” and finding strategies to get better disease control (in malignant diseases). His research group (Group Boelens / Nierkens: U-DANCE) focuses on the development of cord blood derived dendritic cell vaccines (anti-AML, anti-Neuroblastoma). In addition there is a special interest designing a predictable low toxic conditioning regimen using PK/PD-models for e.g. ATG (anti-thymocyte globuline) to better predict the immune-reconstitution (nessasary for optimal effect vaccines). In his group are 4 PostDocs, 5 PhD students and 3 technicians working. He is a frequently invited speaker on international conferences and has over 130 peer-reviewed publications. He is (co-)PI on various phase I/II trials with ATMPs. He is VP elect of the ISCT EU (2016-2018) and will the VP of ISCT EU from 2018-2020 and is also director of the CBA (Cord Blood Association) board (till 2020).
Co-Chair Working Committee Benign Disorders (PID, bone marrow failure syndromes, hemoglobinopathies and metabolic diseases) CIBMTR.
Pediatric Organizing Committee (2013-2016): BMT Tandem Meetings (ASBMT/CIBMTR)
Board of a recently formed “Westhafen Intercontinental group” aiming to integrate/homogenize the EU and USA transplant and cell therapy practices and trying to come beyond phase I/II studies involving ATMPs (advanced therapy medicinal products).
Advisory Board / Consultancy GSK: Genetherapy in Metabolic diseases
Advisory Board Genetherapy Trial (Telethon): X-CGD (X-Linked Chronic Granulomatous Disease)
Associate Editor Cytotherapy (Journal of ISCT: International Society of Cell Therapy)
Advisory Board / Consultancy Novartis: Cell- and Genetherapy
PSIG Organizing Committee (Tandem meetings) 2014 - 2016
Fellowship and Awards
ZonMW TAS (as PI): Development of a cord blood stem cell-derived anti-AML dendritic cell vaccine: Towards powerful "anti-AML immunity" after cord blood transplantation (2014 -2018): 1.7M Euro
ZonMW Priority Medicine Children: Towards Individualized ATG dosing (2012-2016): 0.5M Euro
Various KIKA grants: Cumm. 2M, Villa Joep/Stichting AMMODO: 0.5M, various smaller grants (including Harmanus Ehrhart)
Current active funding: 4.5M
2015: Swammerdam Prijs (van Ned.Vereniging voor Hematologie)
" Elisabeth von Freyburg prijs 2013" voor baanbrekend onderzoek binnen Kinderoncologie